US Stock MarketDetailed Quotes

Adlai Nortye (ANL)

Watchlist
  • 16.130
  • +0.170+1.07%
Close Apr 22 16:00 ET
  • 16.130
  • 0.0000.00%
Post 20:01 ET
856.14MMarket Cap-14.53P/E (TTM)

About Adlai Nortye Company

Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company, which engages in the provision of development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018, and is headquartered in Hangzhou, China.

Company Profile

SymbolANL
Company NameAdlai Nortye
Issue Price23.00
ISINUS00704R1095
Founded2018
CEOMr. Yang Lu
MarketNASDAQ
Employees109
Securities TypeDR
ADS Ratio1 : 3
Fiscal Year Ends12-31
AddressBuilding 6 & 8,1008 Xiangwang Street,Yuhang District
CityHangzhou
ProvinceZhejiang
CountryChina
Zip Code311100
Phone86-571-289-8385

Company Executives

  • Name
  • Position
  • Salary
  • Yang Lu
  • Chief Executive Officer and Chairman of the Board
  • --
  • Dr. Xiaofeng Alex Ye, PhD
  • Chief Financial Officer
  • --
  • Dr. Archie Tse
  • President and Head of Research and Development
  • --
  • Dr. Ping Ji
  • Director
  • --
  • Dr. Lars Erik Birgerson
  • Director
  • --
  • Shaorong Liu
  • Independent Director
  • --
  • Ming Lun Alan Tse
  • Independent Director
  • --
  • Baozhong Wei
  • Independent Director
  • --
  • Dr. Roger Sawhney, M.D.
  • Independent Director
  • --
Market Insights
China Concept Stocks
View More
Middle East conflict spreads to the stock market! How should investors respond?
On April 22 Beijing time, reports indicated that Trump agreed to extend the ceasefire between the US and Iran by 3-5 days rather than indefi Show More